The discovery of a novel orally available CCR5 antagonist, as a therapeutic for HIV-1 infection

被引：0
|
作者：
Nogi, Rena Nishizawa
Nishiyama, Toshihiko
Hisaichi, Katsuya
Minamoto, Chiaki
Matsunaga, Naoki
Hirai, Keisuke
Habashita, Hiromu
Takaoka, Yoshikazu
Toda, Masaaki
Takahashi, Eiji
Imawaka, Haruo
Sagawa, Kenji
Shibayama, Shiro
Fukushima, Daikichi
Maeda, Kenji
Mitsuya, Hiroaki
机构：
[1] ONO PHARMACEUT CO LTD, Dept Med Chem, Mishima, Osaka 6188585, Japan
[2] ONO PHARMACEUT CO LTD, Pharmacokinet Res Labs, Mishima, Osaka 6188585, Japan
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2006年 / 231卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
385-MEDI
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Maraviroc - a CCR5 antagonist for the treatment of HIV-1 infection
    Van Der Ryst, Elna
    FRONTIERS IN IMMUNOLOGY, 2015, 6
  • [2] Pharmacotherapy of HIV-1 Infection: Focus on CCR5 Antagonist Maraviroc
    Latinovic, Olga
    Kuruppu, Janaki
    Davis, Charles
    Le, Nhut
    Heredia, Alonso
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 1497 - 1510
  • [3] Structural model of CCR5 for the discovery of entry inhibitors for the therapeutic intervention of HIV-1 infection
    Das, Debananda
    Maeda, Kenji
    Tsuchiya, Kiyoto
    Mitsuya, Hiroaki
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 231
  • [4] Cenicriviroc, an orally active CCR5 antagonist for the potential treatment of HIV infection
    Klibanov, Olga M.
    Williams, Shannon H.
    Iler, Cameron A.
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2010, 11 (08) : 940 - 950
  • [5] CCR5 antagonists and HIV-1 infection: Bases and consequences of this therapeutic approach
    Psomas, K. C.
    Corbeau, P.
    Reynes, J.
    ANTIBIOTIQUES, 2010, 12 (01): : 27 - 41
  • [6] Vicriviroc: a CCR5 antagonist for treatment-experienced patients with HIV-1 infection
    Kuemmerle, Tim
    Lehmann, Clara
    Hartmann, Pia
    Wyen, Christoph
    Faetkenheuer, Gerd
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (11) : 1773 - 1785
  • [7] HIV-1 infection and CCR5Δ32 homozygosis
    Ballana, Ester
    Este, Jose A.
    FUTURE VIROLOGY, 2012, 7 (07) : 653 - 658
  • [8] Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection
    Kim, D
    Wang, LP
    Caldwell, CG
    Chen, P
    Finke, PE
    Oates, B
    MacCoss, M
    Mills, SG
    Malkowitz, L
    Gould, SL
    DeMartino, JA
    Springer, MS
    Hazuda, D
    Miller, M
    Kessler, J
    Danzeisen, R
    Carver, G
    Carella, A
    Holmes, K
    Lineberger, J
    Schleif, WA
    Emini, EA
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (24) : 3099 - 3102
  • [9] Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist
    Simmons, G
    Clapham, PR
    Picard, L
    Offord, RE
    Rosenkilde, MM
    Schwartz, TW
    Buser, R
    Wells, TNC
    Proudfoot, AEI
    SCIENCE, 1997, 276 (5310) : 276 - 279
  • [10] Discovery of orally available spirodiketopiperazine-based CCR5 antagonists
    Nishizawa, Rena
    Nishiyama, Toshihiko
    Hisaichi, Katsuya
    Hirai, Keisuke
    Habashita, Hiromu
    Takaoka, Yoshikazu
    Tada, Hideaki
    Sagawa, Kenji
    Shibayama, Shiro
    Maeda, Kenji
    Mitsuya, Hiroaki
    Nakai, Hisao
    Fukushima, Daikichi
    Toda, Masaaki
    BIOORGANIC & MEDICINAL CHEMISTRY, 2010, 18 (14) : 5208 - 5223
12345